✦ LIBER ✦

43 Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation

✍ Scribed by A.L. Quittner; B. Ramsey; Q. Dong; K. Yen; J.S. Elborn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

44 Pulmonary exacerbations in a Phase 3

✍ M. Griese; B. Ramsey; S. Rodriguez; K. Yen; J.S. Elborn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

WS6.3 Measures of nutritional status in

✍ D. Borowitz; B. Ramsey; Q. Dong; K. Yen; J.S. Elborn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

46 Hyperpolarized Gas MRI of ivacaftor t

✍ T. Altes; M.A. Johnson; G.W. Miller; J.P. Mugler; L. Flors; J. Mata; C.L. Salina 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

WS6.4 Long-term safety and efficacy of i

✍ E. McKone; H. Li; K. Yen; J.C. Davies 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

WS3.1 The effect of ivacaftor on the rat

✍ Sawicki, G.S.; McKone, E.; Pasta, D.J.; Wagener, J.; Johnson, C.; Konstan, M.W. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 67 KB

WS7.6 Effect of ivacaftor on lung functi

✍ J.C. Davies; H. Sheridan; P.-S. Lee; T. Song; A. Stone; F. Ratjen 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB